[1]刘冬宇,白 劼,白红艳.肝细胞癌组织中Foxp3+调节性T淋巴细胞表达水平及其与肿瘤免疫相关性研究[J].陕西医学杂志,2021,50(8):1019-1022.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.029]
　LIU Dongyu,BAI Jie,BAI Hongyan.Expression level of Foxp3+regulatory T-lymphocyte in hepatocellular carcinoma and its correlation with tumor immunity[J].,2021,50(8):1019-1022.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.029]
点击复制

肝细胞癌组织中Foxp3+调节性T淋巴细胞表达水平及其与肿瘤免疫相关性研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年8期
页码:
1019-1022
栏目:
临床病理
出版日期:
2021-08-05

文章信息/Info

Title:
Expression level of Foxp3+regulatory T-lymphocyte in hepatocellular carcinoma and its correlation with tumor immunity
作者:
刘冬宇; 白 劼; 白红艳
(榆林市星元医院检验科,陕西 榆林 719000)
Author(s):
LIU Dongyu; BAI Jie; BAI Hongyan
(Department of Laboratory Medicine,Xingyuan Hospital of Yulin,Yulin 719000,China)
关键词:
Foxp3+调节性T淋巴细胞;  肝细胞癌;  癌组织;  肿瘤免疫;  免疫功能
Keywords:
Foxp3+regulatory T-lymphocyte;  Hepatocellular carcinoma;  Cancer tissue;  Tumor immunity;  Immune function
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7377.2021.08.029
文献标志码:
A
摘要:
目的:探讨原发性肝细胞癌(HCC)组织中Foxp3+调节性T淋巴细胞(Foxp3+Treg)表达水平及其与肿瘤免疫的相关性。方法:选取40例HCC组织和40例癌旁组织,应用免疫组化方法检测肝癌组织和癌旁组织中的Foxp3+Treg和CD8+ 细胞毒性T淋巴细胞(CD8+CTL)的表达情况,分析Foxp3+Treg与CD8+ CTL的关系,最后分析肿瘤切除术后Foxp3+Treg表达水平的变化。结果:肝细胞癌组织、癌旁组织Foxp3+Treg、CD8+ CTL表达和Foxp3+Treg/CD8+ CTL比值对比差异有统计学意义(均P<0.01); 不同性别、肿瘤位置、术前AFP水平、肿瘤病理分级的HCC患者Foxp3+Treg水平对比差异无统计学意义(均P>0.05),不同肿瘤大小的Foxp3+Treg水平对比差异有统计学意义(P<0.05); 癌组织中Foxp3+Treg与CD8+ CTL呈负相关(r=0.425,P=0.024),Foxp3+Treg越多,CD8+ CTL越少; 术后3个月进行跟踪监测发现,术后患者外周血中的Foxp3+Treg水平为(5.98±1.34)%,手术前为(9.67±2.25)%,术后明显低于手术前,差异具有统计学意义(P<0.05)。结论:肝细胞癌组织中Foxp3+Treg通过抑制CD8+ CTL的增殖,可抑制其抗肿瘤作用; 通过手术可在一定程度上清除免疫抑制,Foxp3+Treg升高与CD8+ CTL降低可能参与肝肿瘤细胞免疫逃逸,因此可以通过检测Foxp3+Treg与CD8+ CTL来评价HCC患者的细胞免疫功能。
Abstract:
Objective:To investigate the expression level of Foxp3+ regulatory T-lymphocyte(Foxp3+Treg)in hepatocellular carcinoma(HCC)and its correlation with tumor immunity.Methods:40 cases of HCC tissues and 40 cases of adjacent tissues were selected.The immunohistochemistry method was used to detect the expression of Foxp3+ Treg and CD8+ cytotoxic T lymphocytes(CD8+ CTL)in HCC tissues and adjacent tissues.The relationship between Foxp3+ Treg and CD8+ CTL was analyzed.Finally, the changes of Foxp3+ Treg level was analyzed after tumor resection.Results:The expression of Foxp3+ Treg,CD8+ CTL and the ratio of Foxp3+ Treg/CD8+ CTL in HCC tissues and adjacent tissues were statistically different(all P<0.01).There was no significant difference in Foxp3+ Treg level in HCC patients with different gender,tumor location,preoperative AFP level,and tumor pathological grade(all P>0.05).There was statistically significant difference in Foxp3+ Treg level in different tumor size(P<0.05).There was a negative correlation between Foxp3+ Treg and CD8+ CTL in cancer tissue(r=0.425,P=0.024).The more Foxp3+ Treg,the less CD8+ CTL.After 3 months of follow-up monitoring,it was found that the Foxp3+ Treg level in the peripheral blood of patients after surgery was significantly lower than that before surgery [(5.98±1.34)% vs.(9.67±2.25)%,P<0.05].Conclusion:Foxp3+ Treg can inhibit the proliferation of CD8+ CTL in HCC.The immunosuppression can be eliminated to a certain extent by surgery.The increase of Foxp3+ Treg and the decrease of CD8+ CTL may be involved in the immune escape of liver tumor cells.Therefore,the detection of Foxp3+ Treg and CD8+ CTL can be considered to evaluate the cellular immune function of HCC patients.

参考文献/References:

[1] 曹绍华,王庆庆,张金冉.索拉非尼联合卡培他滨治疗肝细胞肝癌疗效及对患者血清miR-212和miR-132水平的影响[J].陕西医学杂志,2020,49(5):615-618.
[2] 胡 峻,高月求,孙学华,等.肝积颗粒联合肝动脉化疗栓塞术治疗中晚期肝癌近期疗效研究[J].陕西中医,2020,41(9):1237-1240.
[3] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华消化外科杂志,2017,16(7):635-647.
[4] 艾 宁,冀 宏.肝癌切除术联合放疗治疗原发性肝癌的临床疗效[J].中国老年学杂志,2019,35(21):6144-6146.
[5] Ozakyol A.Global epidemiology of hepatocellular carcinoma epidemiology[J].Journal of Gastrointestinal Cancer,2017,48(3):238-240.
[6] Boguslaw N,Joanna R,Magdalena L,et al.The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases.Part Ⅲ:Polymorphisms of genes involved in Tregs' activation and function[J].Advances in Dermatology & Allergology,2017,34(6):517-525.
[7] Landskron J,Helland O,Torgersen KM,et al.Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients [J].Cancer Immunology Immunotherapy,2015,64(3):337-347.
[8] Rai V,Abdo J,Alsuwaidan AN,et al.Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma[J].Molecular & Cellular Biochemistry,2017,437(24):1-24.
[9] Razek AA,Massoud SM,Azziz MR,et al.Prediction of esophageal varices in cirrhotic patients with apparent diffusion coefficient of the spleen[J].Abdominal Imaging,2015,40(6):1465-1469.
[10] 沈海涛,焦荣红,陆志成,等.原发性肝癌患者外周血CD39+、CD73+调节性T细胞和自然杀伤(NK)细胞的表达及其与肝损伤的相关性[J].现代检验医学杂志,2019,34(1):10-13.
[11] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版)[J].中华肝脏病杂志,2015,23(5):321-327.
[12] Xing HZ,Liu S,Chen XE,et al.A specific immune tolerance toward offspring cells is to exist after the mother lymphocyte infusion[J].Immunobiology,2017,222(4):658-663.
[13] Grant CR,Liberal R,Mielivergani G,et al.Regulatory T-cells in autoimmune diseases:Chal-lenges,controversies and-yet-unanswered questions[J].Autoimnmn Rev,2015,14(2):105-116.
[14] Chen X,Takemoto Y,Deng H,et al.Histi-dine decarboxylase(HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer[J].Oncoimmunology,2017,6(3):290034.
[15] Turcotte M,Spring K,Pommey S,et al.CD73 is associated with poor prognosis in high-gmde serous ovarian caner[J].Cancer Res,2015,75(21):4494-4503.
[16] Antonioli L,Blandizzi C,Malavasi F,et al.Anti-CD73 immunotherapy:A viable way to re-program the tumor microenvironment [J].Oncoimmunology,2016,5(9):1216292.
[17] 周淑燕,卓传尚,柳丽娟,等.PIVKA-II和AFP联合检测对原发性肝癌的诊断价值[J].现代检验医学杂志,2017,32(1):69-71,76.
[18] 李 炜,曾静媛,罗 波,等.膀胱癌患者高表达活化的CD4+记忆性T细胞和CD8+T细胞和低表达M0巨噬细胞与临床预后佳有关[J].细胞与分子免疫学杂志,2020,36(2):97-103.
[19] 姜艳丽,刘 磊,王雪野,等.外周血 CD4+、CD25+、CD127调节性 T 细胞在恶性肿瘤患者免疫功能评估中的作用[J].中国实验诊断学,2015,19(7):1117-1120
[20] Lms P,Stm G,Ishak R,et al.Regulatory T cell and forkhead box protein 3 as modulators of immune homeostasis[J].Frontiers in Immunology,2017,605(8):1-24.
[21] 韩丽芳,赵昌林.肝癌微环境中 Foxp3+调节性 T 细胞对肿瘤免疫抑制作用的研究[J].中国现代医药杂志,2019,21(2):9-12.
[22] 尹承芬,秦庆华,董 宁.调节性T细胞通过膜结合转化生长因子β1影响效应性T细胞凋亡[J].中国急救复苏与灾害医学杂志,2013,8(3):215-219.
[23] 姚家喜,秦玉洁,单永玮,等.转移性肾癌中 PD-1 与 Treg 的表达及其预后预测价值[J].中国肿瘤临床,2018,45(19):980-984.
[24] 杜娜雯,白日兰,崔久嵬.肿瘤免疫逃逸机制及治疗策略[J].中国肿瘤生物治疗杂志,2019,26(4):454-462.

相似文献/References:

[1]何海涛,王智翔,张小弟,等.趋化因子配体13在肝细胞癌组织中的表达及与临床病理特征和预后关系[J].陕西医学杂志,2021,50(2):236.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.028]
　HE Haitao,WANG Zhixiang,ZHANG Xiaodi,et al.Expression of CXCL13 in hepatocellular carcinoma and its correlation with clinicopathological features and prognosis[J].,2021,50(8):236.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.028]
[2]黄丽银,斯 韬,梁 婷,等.丙酮酸脱氢酶激酶4在肝细胞癌中的作用研究进展[J].陕西医学杂志,2023,52(7):934.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.036]
　HUANG Liyin,SI Tao,LIANG Ting,et al.Research progress on role of pyruvate dehydrogenase kinase 4 in hepatocellular carcinoma[J].,2023,52(8):934.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.036]
[3]廖莹莹,张荣臻,舒发明,等.硒在慢性肝病中的作用研究进展[J].陕西医学杂志,2023,52(12):1782.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.034]
　LIAO Yingying,ZHANG Rongzhen,SHU Faming,et al.Research progress on role of selenium in chronic liver disease[J].,2023,52(8):1782.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.034]

备注/Memo

备注/Memo:
基金项目:陕西省科技计划项目(2021SF-044)
更新日期/Last Update: 2021-08-05